News | November 13, 2023
Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr
US business grew by +12.8% YoY
US business grew by +12.8% YoY
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
The company has entered into a three-year Deferred Prosecution Agreement
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Subscribe To Our Newsletter & Stay Updated
